Allogene Therapeutics, Inc. (ALLO) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-15

Key Insights

Allogene Therapeutics is conducting a $175 million public offering of 87.5 million shares of common stock at $2 per share, which could provide additional capital to fund the company's clinical trials and research and development.
The company has granted the underwriters a 30-day option to purchase up to an additional 13.125 million shares, which could increase the total proceeds from the offering.
Allogene plans to use the net proceeds from the offering for general corporate purposes, including funding clinical trials, research and development, and capital expenditures.

Want the newest filings?

This analysis covers the filing from 2026-04-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-13

Allogene announced positive interim results from its pivotal Phase 2 ALPHA3 trial of cemacabtagene ansegedleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL), with 58.3% of patients in the cema-cel arm achieving minimal residual disease (MRD) negativity compared to 16.7% in the observation arm.
Cema-cel was generally well-tolerated, with no serious adverse events related to treatment and no cases of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) or graft-versus-host disease (GvHD) observed.
The ALPHA3 trial is expected to enroll approximately 220 patients, with an interim EFS analysis planned for mid-2027 and the primary EFS analysis in mid-2028, which if positive could support a Biologics License Application (BLA) submission.

Filed: 2026-04-13

Allogene Therapeutics has suspended its common stock offering under the existing sales agreement, likely to focus on a new proposed underwritten public offering of its common stock.
The company has not provided any details about the proposed public offering, such as the size, timing or purpose, which creates some uncertainty for investors.
Suspension of the existing sales agreement and a new public offering could signal Allogene is seeking to raise additional capital, potentially for expansion, development or other corporate purposes.

Other reports for Allogene Therapeutics, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.